The study was designed as a superiority trial with
80% power to detect an absolute difference between
the two treatment groups of 10 percentage
points in cure rates (85% vs. 95%) in the
population that could be evaluated, at an alpha
level of 0.05. Assuming a 20% attrition rate, we
calculated that 524 patients (262 in each group)
needed to be enrolled. The prespecified secondary
outcomes were cure rates at the end of treatment
and at the 1-month follow up visit; cure
rates in the adult and pediatric populations; cure
rates among patients with cellulitis, abscess, or
mixed abscess and cellulitis (defined as separate
lesions of abscess and cellulitis) at the test-ofcure
visit; and adverse-event rates. Comparisons
between groups were performed with the use of
Pearson’s chi-square test, Fisher’s exact test, or
an analysis-of-variance test, as appropriate; all tests
were two-sided. Interim analyses for safety were
performed by an independent data and safety
monitoring committee. Findings from the trial
are described in accordance with Consolidated
Standards of Reporting Trials (CONSORT) guidelines.
14